Akcea Therapeutics Inc (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals Inc, has named Michael D Price as its new executive vice president and chief financial officer, it was reported on Monday.
In the new role, Price will manage financial operations at the company including managing financial strategies and activities related to clinical and regulatory functions, commercial sales, marketing, manufacturing and supply chain.
Price has over 25 years of experience in the pharmaceutical industry. Prior to joining Akcea, he served as EVP and CFO and was elected to the company's board of directors of Novelion Therapeutics. He has also served as VP and CFO at Noven Pharmaceuticals Inc from 2007 to 2016. From 1992 to 2006, he has worked at Bentley Pharmaceuticals Inc serving as VP, CFO, treasurer and secretary. He was also a member of Bentley's board of directors for nine years.
Futura Medical appoints Market Performance Group as new US distribution partner for Eroxon
MaaT Pharma to seek review after CHMP negative opinion on MaaT013 application
Sensei Biotherapeutics changes name to Faeth Therapeutics
Datavault AI and Wellgistics Health plan DelivMeds AI healthcare venture
Intensity Therapeutics receives Cancer Treatment Technology Innovator of the Year award
Solvonis Therapeutics appoints Water Tower Research to strengthen US market positioning
Atrium Therapeutics announces inducement grants to seven new employees
GXO appointed to manage NHS England bowel cancer home testing kits